| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Kiniksa Pharmaceuticals International, Plc's insiders have reduced their positions by a net 4,600 shares worth roughly $369K.
Classified under Pharmaceuticals (Health Care sector), KNSA's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 2.74M | - | - | |
| CEO | 92.3K | $7.32M | - | |
| Other | 69.9K | $5.54M | - | |
| Other | 29.1K | $2.33M | - | |
| Other | 23.1K | $1.13M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 5, 2025 | Tessari Eben | Chief Operating Officer | Sale+OE10b5-1 | 98,660 | $35.54 | $3,506,277.66 | -68.9% | +14.8% | +118.2% | |
| Sep 4, 2025 | Moat Ross | Chief Corp. &Comm. Officer | Sell10b5-1 | 3,523 | $35.31 | $124,397.13 | -27.2% | +14.3% | +119.4% | |
| Sep 3, 2025 | Tessari Eben | Chief Operating Officer | Sale+OE10b5-1 | 15,091 | $35.50 | $535,730.50 | -25.3% | +12.9% | +126.8% | |
| Sep 3, 2025 | Megna Michael R | Chief Accounting Officer | Sale+OE10b5-1 | 11,000 | $34.84 | $383,240.00 | -22.4% | +12.9% | +126.8% | |
| Aug 18, 2025 | Tessari Eben | Chief Operating Officer | Sale+OE10b5-1 | 16,200 | $33.77 | $547,141.00 | -28.7% | +22.8% | +135.7% | |
| Aug 14, 2025 | Malley Thomas67 | Director | Sale+OE | 177,769 | $32.96 | $5,859,815.05 | -93.4% | +21.9% | +130.6% | |
| Aug 6, 2025 | Paolini John F.51 | Chief Medical Officer | Sale+OE10b5-1 | 29,325 | $32.55 | $954,528.75 | -33.8% | +17.8% | +133.8% | |
| Aug 5, 2025 | Tessari Eben | Chief Operating Officer | Sale+OE10b5-1 | 138,614 | $33.20 | $4,602,369.80 | -73.5% | +13.3% | +136.1% | |
| Aug 4, 2025 | Ragosa Mark | Chief Financial Officer | Sale+OE10b5-1 | 18,889 | $32.89 | $621,259.21 | -41.2% | +13.7% | +130.6% | |
| Aug 4, 2025 | Megna Michael R | Chief Accounting Officer | Sale+OE10b5-1 | 17,000 | $32.35 | $549,950.00 | -34.0% | +13.7% | +130.6% |